ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
127.308,80
-0,95%
S&P 500
6.144,15
0,24%
US Dollar vs BRL
5,7225
0,01%
Bitcoin
97.195,14
0,59%
Brent Oil
75,485
-0,44%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Journey Medical Corporation (DERM)

  7. Journey Medical Corporation (DERM) Notícias

DERM

Journey Medical (DERM)

Journey Medical Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:DERM
DataHoraFonteTítuloCódigoCompanhia
05/02/202518:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DERMJourney Medical Corporation
23/01/202510:30GlobeNewswire Inc.Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of RosaceaNASDAQ:DERMJourney Medical Corporation
12/11/202418:01GlobeNewswire Inc.Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
04/11/202409:00GlobeNewswire Inc.Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of RosaceaNASDAQ:DERMJourney Medical Corporation
25/10/202409:30GlobeNewswire Inc.Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology ConferenceNASDAQ:DERMJourney Medical Corporation
03/10/202409:30GlobeNewswire Inc.Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceNASDAQ:DERMJourney Medical Corporation
09/09/202409:30GlobeNewswire Inc.Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) ConferenceNASDAQ:DERMJourney Medical Corporation
04/09/202409:15GlobeNewswire Inc.Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:DERMJourney Medical Corporation
13/08/202417:05GlobeNewswire Inc.Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
12/08/202417:01GlobeNewswire Inc.Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
06/08/202417:01GlobeNewswire Inc.Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024NASDAQ:DERMJourney Medical Corporation
01/08/202417:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DERMJourney Medical Corporation
11/07/202417:05GlobeNewswire Inc.Journey Medical Corporation Appoints Michael C. Pearce to Board of DirectorsNASDAQ:DERMJourney Medical Corporation
15/05/202417:01GlobeNewswire Inc.Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company ShowcaseNASDAQ:DERMJourney Medical Corporation
14/05/202417:46Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DERMJourney Medical Corporation
13/05/202417:01GlobeNewswire Inc.Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
07/05/202409:30GlobeNewswire Inc.Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024NASDAQ:DERMJourney Medical Corporation
01/05/202417:01GlobeNewswire Inc.Journey Medical Corporation Appoints Joseph Benesch as Chief Financial OfficerNASDAQ:DERMJourney Medical Corporation
25/04/202409:30GlobeNewswire Inc.Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024NASDAQ:DERMJourney Medical Corporation
21/03/202417:01GlobeNewswire Inc.Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
18/03/202409:30GlobeNewswire Inc.Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of RosaceaNASDAQ:DERMJourney Medical Corporation
15/03/202409:30GlobeNewswire Inc.Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024NASDAQ:DERMJourney Medical Corporation
13/03/202409:30GlobeNewswire Inc.Journey Medical Corporation to Participate in the 36th Annual ROTH ConferenceNASDAQ:DERMJourney Medical Corporation
11/03/202409:30GlobeNewswire Inc.Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual MeetingNASDAQ:DERMJourney Medical Corporation
05/01/202410:30GlobeNewswire Inc.Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat RosaceaNASDAQ:DERMJourney Medical Corporation
02/01/202418:05GlobeNewswire Inc.Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 MillionNASDAQ:DERMJourney Medical Corporation
15/12/202318:46Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DERMJourney Medical Corporation
06/12/202310:00GlobeNewswire Inc.Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat RosaceaNASDAQ:DERMJourney Medical Corporation
07/11/202318:01GlobeNewswire Inc.Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
31/10/202309:30GlobeNewswire Inc.Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023NASDAQ:DERMJourney Medical Corporation
 Apresentando as notícias mais relevantes sobre:NASDAQ:DERM

Seu Histórico Recente

BOV
PDGR3
PDG REALT ON
BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
PRIO3
PETRORIO ON
BOV
TELB4
TELEBRAS PN
BOV
BRAV3
Brava Energia ON
BOV
GFSA3
GAFISA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios